
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, DC 20549

FORM 8-K

**CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): March 9, 2017

GlycoMimetics, Inc.

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction
of incorporation)

001-36177
(Commission File Number)

06-1686563
(IRS Employer
Identification No.)

**9708 Medical Center Drive
Rockville, MD 20850**
(Address of principal executive offices, including zip code)

(240) 243-1201
(Registrant's telephone number, including area code)

N/A
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-
-

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On March 9, 2017, the Board of Directors (the “*Board*”) of GlycoMimetics, Inc. (the “*Company*”) appointed Scott Koenig, M.D., Ph.D. to serve as a director of the Company and a member of the Nominating and Corporate Governance Committee of the Board. Dr. Koenig will serve as a Class II director whose term will expire at the 2019 Annual Meeting of Stockholders. There is no arrangement or understanding between Dr. Koenig and any other person pursuant to which he was selected as a director of the Company, and there is no family relationship between Dr. Koenig and any of the Company’s other directors or executive officers. The Company is not aware of any transaction involving Dr. Koenig requiring disclosure under Item 404(a) of Regulation S-K. Additional information about Dr. Koenig is set forth below.

Scott Koenig, M.D., Ph.D., age 64, has served as a member of our Board since March 2017. Dr. Koenig has served as President and Chief Executive Officer and a director of MacroGenics, Inc., a public company (NASDAQ: MGNX) since September 2001 and was one of its co-founders. Prior to joining MacroGenics, Dr. Koenig served as Senior Vice President of Research at MedImmune, Inc., where he participated in the selection and maturation of their product pipeline. From 1984 to 1990, he worked in the Laboratory of Immunoregulation at the National Institute of Allergy and Infectious Diseases at the National Institutes of Health, where he investigated the immune response to retroviruses and studied the pathogenesis of AIDS. Dr. Koenig currently serves as Chairman of the Board of Directors of Applied Genetic Technologies Corporation, a public company (NASDAQ: AGTC), and the Children’s Research Institute. Additionally, Dr. Koenig serves on the Board of Directors of Children’s National Medical Center, the International Biomedical Research Alliance, and the Biotechnology Innovation Organization.

In accordance with the Company’s compensation policy for non-employee directors, upon his appointment as a director, Dr. Koenig was granted a nonqualified stock option to purchase 22,000 shares of the Company’s common stock at an exercise price of \$6.59, the closing price of the Company’s common stock on the date of grant. This option will vest and become exercisable in three equal installments on the first, second and third anniversaries of the date of grant subject to Dr. Koenig’s Continuous Service (as defined in the Company’s 2013 Equity Incentive Plan) through such vesting periods. Additionally, Dr. Koenig will be entitled to receive a \$35,000 annual retainer for his service as director and a \$4,000 annual retainer for his service on the Nominating and Corporate Governance Committee. At each annual stockholder meeting following which Dr. Koenig’s term as a director continues, Dr. Koenig will be entitled to receive an additional nonqualified stock option to purchase 11,000 shares of the Company’s common stock, which option will vest and become exercisable over a one-year period following the date of grant. Dr. Koenig has also entered into the Company’s standard form of indemnification agreement.

Resignation of John J. Baldwin, Ph.D. as a Member of the Board of Directors

On March 9, 2017, John J. Baldwin Ph.D., notified the Board of his intention to resign as a director of the Company at the conclusion of the Company’s 2017 Annual Meeting of Stockholders to be held on May 25, 2017. Dr. Baldwin will remain a Member of the Nominating and Corporate Governance Committee and Audit Committee of the Board until the conclusion of the 2017 Annual Meeting of Stockholders.

“On behalf of the Board and the entire GlycoMimetics team, we wish to thank Jack for his service over the years and wish him well in his future endeavors. Jack was a founding board member of GlycoMimetics and his guidance has been invaluable to the Company,” said Rachel K. King, Chief Executive Officer of the Company.

Item 7.01 Regulation FD Disclosure.

On March 13, 2017, the Company issued a press release announcing Dr. Koenig's appointment to the Board. A copy of this press release is furnished herewith as Exhibit 99.1 to this Current Report. The information contained in the press release furnished as Exhibit 99.1 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "*Exchange Act*"), and is not incorporated by reference into any of the Company's filings under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as shall be expressly set forth by specific reference in any such filing.

Item 9.01 Exhibits.

(d) Exhibits

Exhibit Number	Exhibit Description
99.1	Press Release dated March 13, 2017, "GlycoMimetics Appoints Scott Koenig of Macrogenics to Board of Directors."

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

GLYCOMIMETICS, INC.

Date: March 13, 2017

By: /s/ Brian M. Hahn
Brian M. Hahn
Chief Financial Officer

EXHIBIT INDEX

Exhibit Number	Exhibit Description
99.1	Press Release dated March 13, 2017, "GlycoMimetics Appoints Scott Koenig of Macrogenics to Board of Directors."



**GLYCOMIMETICS APPOINTS SCOTT KOENIG OF MACROGENICS
TO BOARD OF DIRECTORS**

*Two Long-Time Board Members to Step Down
After Company's 2017 Annual Meeting*

ROCKVILLE, MD, MARCH 13, 2017 – GlycoMimetics, Inc. (NASDAQ: GLYC) announced today the appointment of Scott Koenig, M.D., Ph.D., to its Board of Directors. Dr. Koenig is President and Chief Executive Officer and a member of the Board of Directors of MacroGenics (NASDAQ: MGNX), a company specializing in antibody-based therapies for cancers and other diseases. He also serves as Chairman of the Board of the Applied Genetic Technologies Corporation (NASDAQ: AGTC).

“We are delighted to have someone with the breadth and depth of Dr. Koenig’s scientific and business expertise join our Board of Directors as we move our portfolio of product candidates into later stages of clinical development and closer to commercialization,” said *Rachel King*, CEO of GlycoMimetics. “His more than 30 years of accomplishment and leadership in research and biotechnology, and his specific work at the helm of a company dedicated to cancer therapeutics, will be true assets to the GlycoMimetics team.”

Dr. Koenig has been President, CEO and a director of MacroGenics since 2001 and was one of the company’s founders. Previously, he was Senior Vice President of Research at MedImmune, participating in the selection and maturation of the company’s product pipeline. Before that, he worked in the National Institute of Allergy and Infectious Diseases’ Laboratory of Immunoregulation. In addition to serving as Chair of the Applied Genetic Technologies Corporation, he also serves as a member of the Board of Directors of the Biotechnology

Innovation Organization (BIO) and the International Biomedical Research Alliance, and co-chairs the Scientific Advisory Board of the Institute for Bioscience and Biotechnology Research (IBBR) at the University of Maryland. Previously, he served as a member of the Scientific Management Review Board at the NIH, and of the Board of Directors of Children's National Health System, where he was also the Chairman of the Board of the Children's Research Institute. He received his M.D. from the University of Texas Health Science Center in Houston, and his Ph.D. and A.B. from Cornell University.

"I'm honored to serve on the Board of Directors of GlycoMimetics, and to help guide their efforts to advance their promising drug candidates," said Dr. Koenig. "I've observed many biotechnology companies as they have worked through the drug development and approval process, and am particularly impressed with the potential of GlycoMimetics and its product candidate portfolio. We share a dedication to making a meaningful difference for those facing unmet medical needs."

In addition to the appointment of Dr. Koenig, GlycoMimetics also announced that two of its long-standing Board members would be stepping down. Franklin Top, Jr., M.D., will not be running for re-election when his term expires after the Company's upcoming Annual Meeting. John J. Baldwin, Ph.D., has also notified the Board of his intention to resign, effective after the GlycoMimetics Annual Meeting.

"I am so grateful for the insights and contributions that Drs. Top and Baldwin have provided to the GlycoMimetics team over the years they have served on our Board of Directors," said Mrs. King. "They have each played a critical role in the success of GlycoMimetics, and they will be sincerely missed."

About GlycoMimetics, Inc.

GlycoMimetics is a clinical-stage biotechnology company focused on cancer and sickle cell disease. GlycoMimetics' most advanced drug candidate, rivipansel, a pan-selectin antagonist, is being developed for the treatment of vaso-occlusive crisis in sickle cell disease and is being evaluated in a Phase 3 clinical trial being conducted by its strategic collaborator, Pfizer.

GlycoMimetics' wholly-owned drug candidate, GMI-1271, an E-selectin antagonist, is being evaluated in an ongoing Phase 1/2 clinical trial as a potential treatment for AML and in a Phase 1 clinical trial in multiple myeloma. GlycoMimetics has also recently initiated a clinical trial with a third drug candidate, GMI-1359, a combined CXCR4 and E-selectin antagonist. GlycoMimetics is located in Rockville, MD in the BioHealth Capital Region. Learn more at www.glycomimetics.com.

Forward-Looking Statements

This press release contains forward-looking statements regarding GlycoMimetics' planned activities with respect to the clinical development of its drug candidates, GMI-1271 and GMI-1359. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the availability and timing of data from ongoing clinical trials, the uncertainties inherent in the initiation of future clinical trials, whether interim results from a clinical trial will be predictive of the final results of the trial or results of early clinical trials will be indicative of the results of future trials, expectations for regulatory approvals, availability of funding sufficient for GlycoMimetics' foreseeable and unforeseeable operating expenses and capital expenditure requirements, other matters that could affect the availability or commercial potential of GlycoMimetics' drug candidates and other factors discussed in the "Risk Factors" section of GlycoMimetics' Annual Report on Form 10-K that was filed with the U.S. Securities and Exchange Commission on February 29, 2016, and other filings GlycoMimetics makes with the Securities and Exchange Commission from time to time. In addition, the forward-looking statements included in this press release represent GlycoMimetics' views as of the date hereof. GlycoMimetics anticipates that subsequent events and developments may cause its views to change. However, while GlycoMimetics may elect to update these forward-looking statements at some point in the future, GlycoMimetics specifically disclaims any obligation to do so, except as may be required by law. These forward-looking statements should not be relied upon as representing GlycoMimetics' views as of any date subsequent to the date hereof.

###

Source: GlycoMimetics

Investor Contact:

Shari Annes

Phone: 650-888-0902

Email: sannes@annesassociates.com

Media Contact:

Jamie Lacey-Moreira

Phone: 410-299-3310

Email: jamielacey@presscommpr.com
